Other information and services: www.belgium.be
Openaid

SI-Improving treatment and outcome of newborns with asphyxia in the Global South

Disclaimer: Country borders do not necessarily reflect the Belgian Government's official position.

General

CD2022TEA505A101 01/09/2022 - 31/08/2027 Hypoxic ischemic encephalopathy (HIE) describes the brain damage after oxygen deprivation before, during or after birth (perinatal asphyxia). It is the cause of nearly 600.000 deaths worldwide every year, of which 99% occur in low- and middle-income countries (LIMC). Additionally it leads to a substantial burden of disease due to long-term neurological disability in survivors. Although therapeutic cooling in HIE showed a significant decrease in handicap in high-income countries, studies in LIMC did not show positive results and even a higher mortality. Therefore, new ways of neuroprotection are needed for LIMC. 2-Iminobiotin (2-IB) 2-IB is a selective inhibitor of inducible and neuronal nitric oxide synthase. It was shown in animal research to decrease the devastating effects of HIE and a phase IIa Clinical Trial, conducted in Kinshasa by the research group of Prof. Biselele, showed its safety. We want to study this medication in three hospitals in Kinshasa and, if results are positive, introduce it in Congo and Sub-Saharan African countries to decrease mortality and severe morbidity in HIE. With this study we also want to expand the knowledge in neonatology and establish the neonatology service in UNIKIN as a research and teaching center for neonatal medicine in LIMC. In this way we acknowledge that not all neonatal therapies are feasible and successful in LIMC, which means that trials in LIMC are needed to confirm its efficiency. By a female Congolese supervisor and PhD and involvement of other female specialists we also want to increase the involvement of women in scientific medical research and education in DR Congo. As last important step, we are expanding the network of collaboration with local and international organisations. There is a collaboration with ENABEL and we are exploring collaborations with Memisa and the Laerdal foundation to evolve to a better network for research and education.

General information

Title
SI-Improving treatment and outcome of newborns with asphyxia in the Global South
ID
XM-DAC-2-10-10677
Start date
End date
Activity status
Implementation
Budget
€131.533
Actor
VLIR-UOS - Vlaamse Interuniversitaire Raad - Flemish Interuniversity Council
Country
CONGO (DEMOCRATIC REP.)
Sector
Health - Medical research
Aid type
Core support to NGOs, other private bodies, PPPs and research institutes
Priority partner country
Yes
Fragile state
Yes
Least developed country
Yes
Budgetline
54 41 452501 Steun aan VLIR mbt de realisatie van de doelen van de gemeenschappelijke strategische kaders
Finance type
GRANT
Tied status
No
Flow type
ODA